NcXHF

GERBER, PAIK, AND DOWLATI
Disclosures of Potential Conflicts of Interest
Relationships are considered self-held and compensated unless otherwise noted. Relationships marked “L” indicate leadership positions. Relationships marked “I” are those held by an immediate
family member; those marked “B” are held by the author and an immediate family member. Institutional relationships are marked “Inst.” Relationships marked “U” are uncompensated.
Employment: None. Leadership Position: None. Stock or Other Ownership Interests: David E. Gerber, Gilead Sciences. Honoraria: Paul K. Paik, Celgene.
Consulting or Advisory Role: David E. Gerber, Bristol-Myers Squibb (Inst), Genentech (Inst). Paul K. Paik, Celgene, Threshold Pharmaceuticals. Speakers’
Bureau: None. Research Funding: David E. Gerber, ArQule (Inst), Celgene (Inst), Genentech (Inst), ImClone Systems (Inst), Immunogen (Inst), Synta (Inst).
Paul K. Paik, AstraZeneca, GlaxoSmithKline. Patents, Royalties, or Other Intellectual Property: David E. Gerber, Royalties from Decision Support in
Medicine from the Clinical Decision Support–Oncology online program, royalties from Oxford University Press from two books. Expert Testimony: None.
Travel, Accommodations, Expenses: David E. Gerber, ArQule, Eli Lilly, Lilly. Other Relationships: None.
|References
1. Travis WD. Pathology of lung cancer. Clin Chest Med. 2011;32:669-
692.
2. Travis WD, Bramilla E, Müller-Hermelink HK, et al (eds). World Health
Organization Classifıcation of Tumours. Pathology and Genetics of Tumours
of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press; 2004.
3. Rekhtman N, Ang DC, Sima CS, et al. Immunohistochemical algorithm
for differentiation of lung adenocarcinoma and squamous cell
carcinoma based on large series of whole-tissue sections with validation
in small specimens. Mod Pathol. 2011;24:1348-1359.
4. Govindan R, Ding L, Griffıth M, et al. Genomic landscape of non-small
cell lung cancer in smokers and never-smokers. Cell. 2012;150:1121-
1134.
5. Hammerman PS, Sos ML, Ramos AH, et al. Mutations in the DDR2
kinase gene identify a novel therapeutic target in squamous cell lung
cancer. Cancer Discov. 2011;1:78-89.
6. Paik PK, Hasanovic A, Wang L, et al. Multiplex testing for driver mutations
in squamous cell lung cancers. J Clin Oncol. 2012; 30:(suppl;
abstr 7505).
7. Weiss J, Sos ML, Seidel D, et al. Frequent and focal FGFR1 amplifıcation
associates with therapeutically tractable FGFR1 dependency in
squamous cell lung cancer. Sci Transl Med. 2010;2:62ra93.
8. Cancer Genome Atlas Research Network. Comprehensive genomic
characterization of squamous cell lung cancers. Nature. 2012;489:519-
525.
9. Zhang J, Zhang L, Su X, et al. Translating the therapeutic potential of
AZD4547 in FGFR1-amplifıed non-small cell lung cancer through the
use of patient-derived tumor xenograft models. Clin Cancer Res. 2012;
18:6658-6667.
10. Wynes MW, Hinz TK, Gao D, et al. FGFR1 mRNA and protein expression,
not gene copy number, predict FGFR TKI sensitivity across all
lung cancer histologies. Clin Cancer Res. 2014;20:3299-3309.
11. Wang R, Wang L, Li Y, et al. FGFR1/3 tyrosine kinase fusions defıne a
unique molecular subtype of non-small cell lung cancer. Clin Cancer
Res. 2014;20:4107-4114.
12. Kim HR, Kim DJ, Kang DR, et al. Fibroblast growth factor receptor 1
gene amplifıcation is associated with poor survival and cigarette smoking
dosage in patients with resected squamous cell lung cancer. J Clin
Oncol. 2013;31:731-737.
13. Heist RS, Mino-Kenudson M, Sequist LV, et al. FGFR1 amplifıcation
in squamous cell carcinoma of the lung. J Thorac Oncol. 2012;7:1775-
1780.
14. Nogova L, Sequist L, Cassier PA, et al. Targeting FGFR1-amplifıed
lung squamous cell carcinoma with the selective pan-FGFR inhibitor
BGJ398. J Clin Oncol. 2014;32 (suppl; abstr 8034).
15. Paik PK, Shen R, Ferry D, et al. A phase 1b open-label multicenter
study of AZD4547 in patients with advanced squamous cell lung cancers:
preliminary antitumor activity and pharmacodynamic data.
J Clin Oncol. 2014;32:5s (suppl; abstr 8035).
16. Rekhtman N, Paik PK, Arcila ME, et al. Clarifying the spectrum of
driver oncogene mutations in biomarker-verifıed squamous carcinoma
of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1
mutations. Clin Cancer Res. 2012;18:1167-1176.
17. Yamamoto H, Shigematsu H, Nomura M, et al. PIK3CA mutations
and copy number gains in human lung cancers. Cancer Res. 2008;68:
6913-6921.
18. Okudela K, Suzuki M, Kageyama S, et al. PIK3CA mutation and amplifıcation
in human lung cancer. Pathol Int. 2007;57:664-671.
19. Xu C, Fillmore CM, Koyama S, et al. Loss of Lkb1 and Pten leads to
lung squamous cell carcinoma with elevated PD-L1 expression. Cancer
Cell. 2014;25:590-604.
20. Soria JC, Lee HY, Lee JI, et al. Lack of PTEN expression in non-small
cell lung cancer could be related to promoter methylation. Clin Cancer
Res. 2002;8:1178-1184.
21. Spoerke JM, O’Brien C, Huw L, et al. Phosphoinositide 3-kinase
(PI3K) pathway alterations are associated with histologic subtypes and
are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical
models. Clin Cancer Res. 2012;18:6771-6783.
22. Engelman JA, Chen L, Tan X, et al. Effective use of PI3K and MEK
inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine
lung cancers. Nat Med. 2008;14:1351-1356.
23. Ikeda K, Wang LH, Torres R, et al. Discoidin domain receptor 2 interacts
with Src and Shc following its activation by type I collagen. J Biol
Chem. 2002;277:19206-19212.
24. Olaso E, Labrador JP, Wang L, et al. Discoidin domain receptor 2 regulates
fıbroblast proliferation and migration through the extracellular
matrix in association with transcriptional activation of matrix
metalloproteinase-2. J Biol Chem. 2002;277:3606-3613.
25. Haura EB, Tanvetyanon T, Chiappori A, et al. Phase I/II study of the
Src inhibitor dasatinib in combination with erlotinib in advanced nonsmall-cell
lung cancer. J Clin Oncol. 2010;28:1387-1394.
26. Johnson FM, Bekele BN, Feng L, et al. Phase II study of dasatinib in
patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010;
28:4609-4615.
27. Pitini V, Arrigo C, Di Mirto C, et al. Response to dasatinib in a patient
with SQCC of the lung harboring a discoid-receptor-2 and synchronous
chronic myelogenous leukemia. Lung Cancer. 2013;82:171-172.
28. Dickson MA, Schwartz GK. Development of cell-cycle inhibitors for
cancer therapy. Current Oncology. 2009;16:36-43.
29. Gelbert L, Cai S, Lin X, et al. Preclinical characterization of the CDK4/6
inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-
158 2015 ASCO EDUCATIONAL BOOK | asco.org/edbook